Previous close | 3.0500 |
Open | 3.0500 |
Bid | 2.5500 |
Ask | 3.0000 |
Strike | 165.00 |
Expiry date | 2024-12-20 |
Day's range | 3.0500 - 3.0500 |
Contract range | N/A |
Volume | |
Open interest | 25 |
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.